Client First Capital’s Eli Lilly LLY Stock Holding History

Client First Capital’s Portfolio LLY Stock Details LLY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$828K	Hold	690	–	–	0.33%	18
2026 Q1	$635K	Hold	690	–	–	0.28%	20
2025 Q4	$742K	Hold	690	–	–	0.31%	21
2025 Q3	$526K	Hold	690	–	–	0.23%	18
2025 Q2	$538K	Buy	+690	New	+$536K	0.25%	18

Other funds holding LLY

Lilly Endowment Indiananapolis, Indiana $108B AUM 53.87% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Sapient Capital Indianapolis, Indiana $7.64B AUM 51.51% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Client First Capital's LLY Position: Q2 2026 in Review

Client First Capital held its Eli Lilly (LLY) position steady in Q2 2026 at 690 shares worth $828K. The position accounts for 0.33% of the portfolio, ranked #18.

Client First Capital first reported a position in LLY in Q2 2025 and has held it in 5 quarters since. 2,247 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

Client First Capital held 690 shares of Eli Lilly worth $828K as of Q2 2026.
Client First Capital left its Eli Lilly share count unchanged in Q2 2026.
Eli Lilly made up 0.33% of Client First Capital's portfolio in Q2 2026, its #18 holding.
Client First Capital first reported a position in Eli Lilly in Q2 2025 and has held it in 5 quarters since.
2,247 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Client First Capital's 13F filing for Q2 2026, filed 13 Jul 2026.